Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete
response following frontline therapy, key unmet clinical needs remain including …
response following frontline therapy, key unmet clinical needs remain including …
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide
J Sugita - International journal of hematology, 2019 - Springer
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide has
spread rapidly worldwide. This strategy was initially developed in the setting of bone marrow …
spread rapidly worldwide. This strategy was initially developed in the setting of bone marrow …
Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR
G Fatobene, V Rocha, A St. Martin… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma
undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic …
undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic …
[HTML][HTML] T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation …
J Mariotti, R Devillier, S Bramanti, B Sarina… - Biology of Blood and …, 2018 - Elsevier
Allogeneic hematopoietic stem cell transplantation (SCT) represents a potential curative
strategy for patients with Hodgkin lymphoma (HL) relapsing after autologous SCT (ASCT) …
strategy for patients with Hodgkin lymphoma (HL) relapsing after autologous SCT (ASCT) …
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplantation for patients with …
J Montoro, A Boumendil, H Finel, S Bramanti… - … and Cellular Therapy, 2024 - Elsevier
Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for
preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell …
preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell …
Is post-transplant cyclophosphamide the new methotrexate?
A Mussetti, A Paviglianiti, R Parody… - Journal of Clinical …, 2021 - mdpi.com
Introducing post-transplant, cyclophosphamide (PT-Cy) graft-versus-host disease (GVHD)
prophylaxis in the setting of haploidentical donor transplantation has marked the most …
prophylaxis in the setting of haploidentical donor transplantation has marked the most …
Haploidentical hematopoietic stem cell transplantation followed by 'post-cyclophosphamide': the future of allogeneic stem cell transplant
S Cytryn, M Abdul-Hay - Clinical Hematology International, 2020 - Springer
Allogeneic hematopoietic cell transplant (Allo-HCT) is a potentially curative therapy for many
malignant and nonmalignant hematological diseases. However, a suitable human leukocyte …
malignant and nonmalignant hematological diseases. However, a suitable human leukocyte …
[HTML][HTML] Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation
G Fatobene, BE Storer, RB Salit, SJ Lee… - …, 2018 - pmc.ncbi.nlm.nih.gov
We determined the incidence of disability related to chronic graft-versus-host disease
(bronchiolitis obliterans, grade≥ 2 keratoconjunctivitis sicca, sclerotic features or …
(bronchiolitis obliterans, grade≥ 2 keratoconjunctivitis sicca, sclerotic features or …
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem …
F Giannotti, C De Ramon Ortiz, F Simonetta… - Frontiers in …, 2024 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The …
treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The …
[HTML][HTML] Peripheral blood stem cells versus bone marrow for T cell–replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin …
J Mariotti, R Devillier, S Bramanti, L Giordano… - Biology of blood and …, 2019 - Elsevier
Haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide
(PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) …
(PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) …